Filtered By:
Drug: Warfarin
Education: Study

This page shows you your search results in order of date. This is page number 9.

Order by Relevance | Date

Total 2155 results found since Jan 2013.

Comparison of primary and secondary stroke prevention in patients with nonvalvular atrial fibrillation: Results from the RAFFINE registry
Atrial fibrillation (AF) is a predictor of severe stroke and early death in acute ischemic stroke patients.1 The prevalence of AF has increased as the Japanese population has aged.2 AF has been more common among patients with ischemic stroke than previously reported.3 In particular, AF patients with a history of stroke or TIA have had higher risks for stroke, hemorrhagic events, and death compared to those without.4,5 In these previous studies, most patients received warfarin for anticoagulation therapy.
Source: Journal of Stroke and Cerebrovascular Diseases - November 7, 2022 Category: Neurology Authors: Kazuo Yamashiro, Ryota Tanaka, Sakiko Miyazaki, Katsumi Miyauchi, Hidemori Hayashi, Yuji Nishizaki, Shuko Nojiri, Satoru Suwa, Masataka Sumiyosi, Yuji Nakazato, Takao Urabe, Nobutaka Hattori, Tohru Minamino, Hiroyuki Daida Source Type: research

Apixaban for Patients with Atrial Fibrillation on Hemodialysis: A Multicenter Randomized Controlled Trial
CONCLUSIONS: There was inadequate power to draw any conclusion regarding rates of major or clinically relevant non-major bleeding comparing apixaban and warfarin in patients with AF and ESKD on hemodialysis. Clinically relevant bleeding events were approximately 10-fold more frequent than stroke or systemic embolism among this population on anticoagulation, highlighting the need for future randomized studies evaluating the risks versus benefits of anticoagulation among patients with AF and ESKD on hemodialysis.PMID:36335914 | DOI:10.1161/CIRCULATIONAHA.121.054990
Source: Circulation - November 6, 2022 Category: Cardiology Authors: Sean D Pokorney Glenn M Chertow Hussein R Al-Khalidi Dianne Gallup Pat Dignaco Kurt Mussina Nisha Bansal Crystal A Gadegbeku David A Garcia Samira Garonzik Renato D Lopes Kenneth W Mahaffey Kelly Matsuda John P Middleton Jennifer A Rymer George H Sands Ra Source Type: research

Pharmacogenomics in Stroke and Cardiovascular Disease: State of the Art
Stroke. 2022 Nov 3. doi: 10.1161/STROKEAHA.122.037717. Online ahead of print.ABSTRACTThere is considerable interindividual variability in the response to antiplatelet and anticoagulant therapies, and this variation may be attributable to genetic variants. There has been an increased understanding of the genetic architecture of stroke and cardiovascular disease, which has been driven by advancements in genomic technologies and this has raised the possibility of more targeted pharmaceutical treatments. Pharmacogenetics promises to use a patient's genetic profile to treat those who are more likely to benefit from a particular...
Source: Atherosclerosis - November 3, 2022 Category: Cardiology Authors: Stephanie Ross Kristi Krebs Guillaume Par é Lili Milani Source Type: research

Comparative Effectiveness and Safety Between Apixaban, Dabigatran, Edoxaban, and Rivaroxaban Among Patients With Atrial Fibrillation : A Multinational Population-Based Cohort Study
CONCLUSION: Among patients with AF, apixaban use was associated with lower risk for GIB and similar rates of ischemic stroke or systemic embolism, ICH, and all-cause mortality compared with dabigatran, edoxaban, and rivaroxaban. This finding was consistent for patients aged 80 years or older and those with chronic kidney disease, who are often underrepresented in clinical trials.PRIMARY FUNDING SOURCE: None.PMID:36315950 | DOI:10.7326/M22-0511
Source: Annals of Internal Medicine - October 31, 2022 Category: Internal Medicine Authors: Wallis C Y Lau Carmen Olga Torre Kenneth K C Man Henry Morgan Stewart Sarah Seager Mui Van Zandt Christian Reich Jing Li Jack Brewster Gregory Y H Lip Aroon D Hingorani Li Wei Ian C K Wong Source Type: research

Stroke services in the Middle East and adjacent region: A survey of 34 hospital-based stroke services
ConclusionThis is the first large study on the availability of resources for the management of acute stroke in the MENA+ region. We noted the disparity in stroke care between high-income and low-income countries. Concerted efforts are required to improve stroke care in low-income countries. Accreditation of stroke programs in the region will be helpful.
Source: Frontiers in Neurology - October 28, 2022 Category: Neurology Source Type: research

Successful use of therapeutic anticoagulation therapy in two patients with moderate stroke from the second day of onset: A case report and literature review
CONCLUSION: As a result of this case report, clinical improvement has not been associated with hemorrhagic sequelae of anticoagulant administration on the first day. At this point, we recommend conducting a trial to study the effect of early application of anticoagulants from the first day on clinical outcome, recurrence, and hemorrhagic transfusion of stroke.PMID:36268411 | PMC:PMC9577847 | DOI:10.1016/j.amsu.2022.104726
Source: Annals of Medicine - October 21, 2022 Category: Internal Medicine Authors: Mostafa Meshref Nour Shaheen Rehab Adel Diab Mariam Tarek Desouki Yara Amro Shiamaa M Khairat Mohamed Ali Mahmoud Galal Ahmed Source Type: research

High rates of oral anticoagulation in atrial fibrillation patients observed in a large multi-specialty health system in the Northeast
ConclusionsWe show dramatically increased OAC usage among patients with AF and that NOACs comprise the large majority of OACs compared with previous studies. This suggests an association between widespread adoption of NOACs and increased oral anticoagulation rates. Future directions include assessing barriers to oral anticoagulation and developing interventions to reduce disparity in OAC use between clinics.
Source: Journal of Interventional Cardiac Electrophysiology - October 20, 2022 Category: Cardiology Source Type: research

Using primary care data to assess comparative effectiveness and safety of apixaban and rivaroxaban in patients with nonvalvular atrial fibrillation in the UK: an observational cohort study
Conclusions Among patients with nonvalvular AFib, apixaban was as effective as rivaroxaban in reducing rate of stroke and safer in terms of major bleeding episodes. This head-to-head comparison supports conclusions drawn from indirect comparisons of DOAC trials against warfarin and demonstrates the potential for real-world evidence to fill evidence gaps and reduce uncertainty in both health technology assessment decision-making and clinical guideline development.
Source: BMJ Open - October 17, 2022 Category: General Medicine Authors: Jaksa, A., Gibbs, L., Kent, S., Rowark, S., Duffield, S., Sharma, M., Kincaid, L., Ali, A. K., Patrick, A. R., Govil, P., Jonsson, P., Gatto, N. Tags: Open access, Cardiovascular medicine Source Type: research